Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

1. (currently amended) An inorganic acid salt of sibutramine, which has a structure of ~~Chemical Formula 1, below, the inorganic acid salt being hydrogen sulfate, bromate or phosphate monohydrate.~~ the following Chemical Formula 1:

[Chemical Formula 1]



$X = HSO_4$, Br, $H_2PO_4H_2O$

the inorganic acid salt being hydrogen sulfate, bromate, or phosphate monohydrate.

2. (original) The inorganic acid salt of sibutramine as set forth in claim 1, wherein the sibutramine hydrogen sulfate is a first crystalline sibutramine hydrogen sulfate having an X-ray diffraction pattern in which peaks appear at 2θ values of 6.50, 12.18, 12.38, 12.58, 13.06, 14.00, 16.76, 17.04, 18.06, 19.68, 20.32, 20.63, 21.34, 21.82, 22.28, 22.54, 23.32, 24.50, 25.80, 26.42, 28.24, 28.64, 29.28, and 33.34.

3. (original) The inorganic acid salt of sibutramine as set forth in claim 1, wherein the sibutramine hydrogen sulfate is a second crystalline sibutramine hydrogen

sulfate having an X-ray diffraction pattern in which peaks appear at 2θ values of 5.73, 6.49, 12.18, 12.51, 13.13, 14.02, 14.79, 16.97, 17.38, 20.62, 21.40, 21.83, 22.31, 22.68, 24.51, 24.88, 25.82, 26.45, and 31.60.

4. (original) The inorganic acid salt of sibutramine as set forth in claim 1, wherein the sibutramine hydrogen sulfate is a third crystalline sibutramine hydrogen sulfate having an X-ray diffraction pattern in which peaks appear at 2θ values of 6.64, 10.24, 13.03, 15.04, 17.00, 17.53, 17.08, 19.06, 20.52, 22.72, 23.23, 24.23, 25.70, 26.40, and 27.57.

5. (original) The inorganic acid salt of sibutramine as set forth in claim 1, wherein the sibutramine bromate is crystalline sibutramine bromate having an X-ray diffraction pattern in which peaks appear at 2θ values of 6.96, 11.48, 13.88, 16.64, 17.14, 18.14, 19.68, 20.92, 21.32, 21.86, 22.16, 22.86, 24.30, 26.16, 26.40, 27.42, 28.06, 28.32, 29.52, 31.58, 32.94, 34.54, 37.42, and 37.82.

6. (original) The inorganic acid salt of sibutramine as set forth in claim 1, wherein the sibutramine phosphate monohydrate is crystalline sibutramine phosphate monohydrate having an X-ray diffraction pattern in which peaks appear at 2θ values of 7.66, 10.68, 11.06, 11.50, 14.46, 15.40, 15.74, 17.22, 17.84, 18.08, 18.98, 19.68, 21.18, 21.50, 21.88, 22.84, 23.18, 23.62, 24.42, 24.72, 25.98, 27.52, 28.38, 28.64, and 29.28.

7. (currently amended) A method of preparing [[the]] sibutramine hydrogen sulfate ~~according to claim 1~~, comprising reacting sibutramine and sulfuric acid.

8. (currently amended) A method of preparing [[the]] sibutramine bromate ~~according to claim 1~~, comprising reacting sibutramine and bromic acid.

9. (currently amended) A method of preparing [[the]] sibutramine phosphate or phosphate monohydrate ~~and phosphate monohydrate according to claim 1~~, comprising reacting sibutramine and phosphoric acid.

10. (currently amended) The method as set forth in any one of claims 7 to 9, wherein the reaction takes place in an organic solvent selected from the group consisting of acetone, ethyl acetate, methanol, ethanol, isopropanol, acetonitrile, isopropyl ether, methylethyl ketone, dichloromethane and combinations ~~combination~~ thereof.

11. (currently amended) A pharmaceutical composition ~~for treating or preventing obesity and related disorders, depression, Parkinson's disease, insulin-independent diabetes mellitus or epilepsy, comprising a therapeutically effective amount of the sibutramine hydrogen sulfate, sibutramine bromate or sibutramine phosphate monohydrate according to claim 1~~ comprising an inorganic acid salt of sibutramine represented by the following Chemical Formula 1:

[Chemical Formula 1]



$\underline{X = HSO_4, Br, H_2PO_4H_2O}$

and a pharmaceutically acceptable diluent or carrier.

12. (original) The pharmaceutical composition as set forth in claim 11, wherein the sibutramine hydrogen sulfate, sibutramine bromate or sibutramine phosphate is contained in a therapeutically effective amount of 1 to 50 mg.

13. (currently amended) A method of treating ~~or preventing~~ obesity ~~and related disorders~~, depression, Parkinson's disease, insulin-independent diabetes mellitus or epilepsy, comprising administering ~~the pharmaceutical composition of claim 11.~~ a pharmaceutical composition comprising an inorganic acid salt of sibutramine represented by the following Chemical Formula 1:

[Chemical Formula 1]



$\underline{X = HSO_4, Br, H_2PO_4H_2O}$

and a pharmaceutically acceptable diluent or carrier.

14. (new) The pharmaceutical composition as set forth in claim 11, wherein the composition is for treating obesity, depression, Parkinson's disease, insulin-independent diabetes mellitus, or epilepsy.